Alentemol hydrobromide

Alentemol hydrobromide (U-68553B) (1 μg/kg-1 mg/kg; s.c.; single administration; 45 min) decreases DOPA, DOPAC, and HVA levels (inhibiting dopamine synthesis and metabolism) and increases dopamine levels in mice with postsynaptic cells pre-lesioned by Kainic acid (HY-N2309) as well as in normal mice^[1].
Alentemol hydrobromide (1.0 mg/kg; s.c.; single administration; 30 min) exhibits activity in entering brain tissue and reaching a certain intracerebral concentration in the normal male CF-1 mouse model^[1].
Alentemol hydrobromide (0.1 μg/kg-0.1 mg/kg; s.c.; single administration; recording starts 10 min after administration and lasts for 20 min) significantly inhibits locomotor stimulation in the d-amphetamine-induced hyperlocomotion model in male CF-1 mice^[1].
Alentemol hydrobromide (3 μg/kg-0.3 mg/kg; s.c.; single administration; 30 min) significantly reduces 3-MT levels in the striatum of male CF-1 mice in a normal model^[1].